Epstein File EFTA01113739: Barr, Targeted and CI (DS9)

Epstein Index›Documents›EFTA01113739

⚡IMPACT LEVEL 3 — NOTEWORTHY

Epstein File EFTA01113739: Barr, Targeted and CI (DS9)

General DocumentDate unavailableEFTA011137391 keyword hits

0

views

0

shares

0

reactions

2

persons

4

keywords

7

excerpts

A pharmaceutical investment presentation dated February 2013 for OSE Pharma detailing clinical assets and market opportunities, including Phase 3 studies for advanced lung cancer (NSCLC) and Phase 2 execution for Cystic Fibrosis, with a market opportunity valued at €1.4B. The document contains clinical trial data with survival estimates and confidence intervals (CI) for patient groups. This appears to be a business investment document unrelated to the core subject matter of the case file.

👤 Named in This Document

Bill Barr William Barr

🔑 Evidence Keywords

targeted CI killing cum

📋 Key Excerpts7

PersonKeyword

Excerpt 1

Presentation February 2013 1 EFTA01113739 OSE Pharma Investment Thesis Substantial late stage clinical assets: Phase 3 study for advanced lung cancer (NSCLC): **targeted**

Excerpt 2

Phase 2 execution for Cystic Fibrosis («mucoviscidose» a genetic disorder ) OSE Pharma 3 EFTA01113741 OSE Pharma Market opportunity : €1.4B OSE 2101 **targeted**

Excerpt 3

filed in 2012 OSE Pharma 5 EFTA01113743 OSE Pharma advanced pipeline Drug Mkt Pre clinical Phase I Phase II Phase III discovery application OSE2101: **targeted**